My guess is that all the attention is on vaccine companies like Novavax and Moderna. It looks like the CEO has a very good presentation with enough money to move forward. I look at Market Cap relative to other similar companies, 138 M, and think it should be at least 500 M so significantly undervalued. The insiders have been buying and that generally correlates with growth in share price. Anyway, to answer your question, this stock is a micro-cap, below $5/share so it's not on anyone's radar, YET. Probably a good entry point.
I think anti-virals and therapeutic control of inflamation are the way to go with regard to C-19. Vaccines are a long shot. HIV has been successfully treated but NEVER a vaccine is a good example. HSP90 has repeatedly been validated as an anti-viral target for many years by the way. I think ALDX is onto something that can dramatically improve the treatment of people that are infected. Might take a look at IMUX, also a non-vaccine approach.
Good Luck!
News 
Market Data 
Discover 
AI
